Tofogliflozin (hydrate)
CAY-23509-25 25 mg
Data Sheet: 
SDS:
SDS:
CAS
1201913-82-7
Formulation
A crystalline solid
Purity
≥95%
MW
404,45352
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A potent inhibitor of SGLT2 (Kis = 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2, respectively); selective for SGLT2 (IC50 = 2.9 nM) over other SGLTs (IC50s = >1,500 nM for SGLT1 and 3-6); reduces plasma glucose concentration and increases renal glucose clearance in Zucker diabetic fatty rats in a dose-dependent manner when administered at doses ranging from 3-10 mg/kg; reduces hyperglycemia in non-fasted db/db mice and decreases postprandial hyperglycemia in GK rats, a non-obese model of type 2 diabetes with glucose intolerance
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
